Donepezil increases resistance to induced seizures in a mouse model of Dravet syndrome.
Ann Clin Transl Neurol
; 6(8): 1566-1571, 2019 08.
Article
en En
| MEDLINE
| ID: mdl-31402621
ABSTRACT
De novo loss-of-function mutations in SCN1A are the main cause of Dravet syndrome, a catastrophic encephalopathy characterized by recurrent early-life febrile seizures, a number of other afebrile seizure types that are often refractory to treatment, and behavioral abnormalities including social deficits, motor dysfunction, and cognitive impairment. We previously demonstrated that the reversible acetylcholinesterase inhibitor, Huperzine A, increases seizure resistance in Scn1a mutants. In the present study, we evaluated the therapeutic potential of donepezil, a reversible acetylcholinesterase inhibitor approved by the Food and Drug Administration, in a mouse model of Dravet syndrome (Scn1a+/- ). We found that donepezil conferred robust protection against induced seizures in Scn1a+/- mutants.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Convulsiones
/
Epilepsias Mioclónicas
/
Donepezilo
Límite:
Animals
Idioma:
En
Revista:
Ann Clin Transl Neurol
Año:
2019
Tipo del documento:
Article